S. Opal

J. Marshall, S. Opal, A. Thompson, 2005, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials*

S. Opal, D. Angus, V. Ranieri, 2016, Critical care medicine.

Lessons learned from clinical trials of sepsis

S. Opal, S. Opal, 1995 .

Hemofiltration-absorption systems for the treatment of experimental sepsis: is it possible to remove the "evil humors" responsible for septic shock?

S. Opal, 2000, Critical care medicine.

Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial

S. Opal, D. Angus, T. Calandra, 2009, Critical care medicine.

Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohort

M. Levy, G. Patel, G. Martin, 2019, Journal of Intensive Care.

Sepsis definitions: time for change

Kevin J. Tracey, John C. Marshall, J. Marshall, 2013, The Lancet.

Sepsis defi nitions: time for change

J. Marshall, S. Opal, J. Vincent, 2013 .

The Novel Immunotherapeutic Oligodeoxynucleotide IMT504 Protects Neutropenic Animals from Fatal Pseudomonas aeruginosa Bacteremia and Sepsis

S. Opal, A. Chahin, D. Jobes, 2014, Antimicrobial Agents and Chemotherapy.

Unintended bias, clinical trial results, and the heparin post hoc crossover fallacy

S. Opal, 2004, Critical care medicine.

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

S. Opal, S. LaRosa, 2013, American journal of respiratory and critical care medicine.

RISE-resistant tuberculous meningitis in AIDS patient

S. Opal, D. Horn, D. Hewlett, 1993, The Lancet.

Dual inhibition of interleukin-1β and interleukin-18: a new treatment option for sepsis?

S. Opal, 2014, American journal of respiratory and critical care medicine.

Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe Sepsis

S. Opal, A. Kalil, S. LaRosa, 2011, Shock.

1105: IL-1 Receptor Antagonist Improves Mortality in Severe Sepsis Subset with hemophagocytic Syndrome

S. Opal, J. Carcillo, C. Dinarello, 2013 .

Sepsis: Time to reconsider the concept

S. Opal, H. Masur, J. Carlet, 2008, Critical care medicine.

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*

S. Opal, S. Lowry, W. McGee, 2004, Critical care medicine.

Biomarkers of Infection and Sepsis.

S. Opal, X. Wittebole, 2020, Critical care clinics.

Immunosuppression and Secondary Infection in Sepsis: Part, Not All, of the Story.

S. Opal, D. Angus, 2016, JAMA.

Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis

C. Sprung, S. Opal, B. Light, 2013 .

From the bench to the bedside: The future of sepsis research - Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop

S. Hurd, D. Teres, G. Bernard, 1997 .

Sepsis: frontiers in supportive care, organisation and research

S. Opal, J. Vincent, D. Angus, 2017, Intensive Care Medicine.

Phase 2 trial of eritoran tetrasodium ( E 5564 ) , a Toll-like receptor 4 antagonist , in patients with severe sepsis *

S. Opal, A. Wittek, M. Tidswell, 2009 .

Antibiotic management of suspected nosocomial ICU-acquired infection: Does prolonged empiric therapy improve outcome?

D. Cook, J. Marshall, S. Opal, 2007, Intensive Care Medicine.

Should we continue to test soluble thrombomodulin, or other systemic anticoagulants, as a life-saving therapy for sepsis-induced coagulopathy?

M. Levy, S. Opal, P. Laterre, 2019, Anaesthesia, critical care & pain medicine.

High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*

S. Opal, J. Briegel, J. Kienast, 2006, Critical care medicine.

Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial.

S. Opal, D. Yealy, J. Decruyenaere, 2019, JAMA.

Antibiotics and nephrostomy tube care: preliminary observations. Part I. Bacteriuria.

S. Opal, D. Horn, J. Cronan, 1989, Radiology.

Shock Septic and Fludrocortisone on Mortality in Patients With Effect of Treatment With Low Doses of Hydrocortisone

S. Opal, J. Millo, Julian M. Brown, 2008 .

The Treatment of Sepsis

S. Opal, M. Haller, J. Briegel, 1910, Intensive Care Medicine.

Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock.

S. Opal, J. Vincent, S. Opal, 1999, The Journal of infectious diseases.

Clinical trials for severe sepsis. Past failures, and future hopes.

S. Opal, S. Opal, A. Cross, 1999, Infectious disease clinics of North America.

Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis?

S. Opal, S. Opal, Jonathan Cohen, 1999, Critical care medicine.

Group B streptococcal sepsis in adults and infants. Contrasts and comparisons.

S. Opal, S. Opal, A. Cross, 1988, Archives of internal medicine.

Clinical characteristics, management strategies, and cost implications of a statewide outbreak of enterovirus meningitis.

S. Opal, S. Opal, S. Rice, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Selenium replacement in severe systemic inflammatory response syndrome.

S. Opal, 1999, Critical care medicine.

The PIRO concept: I is for infection

S. Opal, J. Vincent, R. Wunderink, 2003, Critical care.

Baseline severity of sepsis in subjects of the prowess and the Kybersept clinical trials on endogenous anticoagulants.

S. Opal, C. Wiedermann, H. Keinecke, 2006, Shock.

24 – What Is Inflammation? What Is Sepsis? What Is MODS?

S. Opal, E. Patrozou, 2011 .

Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study.

S. Opal, T. Welte, R. Dellinger, 2015, Respiratory medicine.

Clinical impact of novel anticoagulation strategies in sepsis

S. Opal, 2001, Current opinion in critical care.

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

C. Sprung, S. Opal, J. Carcillo, 2004, Intensive Care Medicine.

Immunosuppression and Secondary Infection in Sepsis: Part, Not All, of the Story.

S. Opal, D. Angus, 2016, JAMA.

Differences Between American and German Medical Students and Physicians in Knowledge of Infectious Diseases

S. Opal, S. Opal, H. Lode, 2000, European Journal of Clinical Microbiology and Infectious Diseases.

The Sepsis Text

S. Opal, J. Vincent, J. Carlet, 2002, Springer US.

The Challenge of Emerging Infections and Progressive Antibiotic Resistance

S. Opal, S. Opal, 2006, Intensive Care Medicine in 10 Years.

Bedside Monitoring of Patients with Shock Using a Portable Spatially-resolved Near-infrared Spectroscopy References and Links Study on Shock Monitoring Using a Space-resolved Nirs, " Pibm 2014, Proc. Spie. in Press

Ting Li, Guoqiang Yu, Kai Li, 2022 .

Nosocomial Infection With Multidrug-Resistant and -Susceptible Tuberculosis in 91 Health Care Workers

S. Opal, D. Horn, D. Hewlett, 1995 .

LIMITED TOLERANCE OF OFLOXACIN AND PYRAZINAMIDE PROPHYLAXIS IN HEALTH CARE WORKERS FOLLOWING EXPOSURE TO RIFAMPINISONIAZID- STREPTOMYCIN-ETHAMBUTOL-RESISTANT TUBERCULOSIS

S. Opal, D. Horn, D. Hewlett, 1995 .

S. Hurd, D. Teres, G. Bernard, 1997 .